Cognition Therapeutics Overview
- Founded
-
2007
- Status
-
Public
- Employees
-
21
- Stock Symbol
-
CGTX
- Share Price
-
$1.84
- (As of Friday Closing)
Cognition Therapeutics General Information
Description
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate, CT1812, is an orally delivered, small molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
Contact Information
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
- 2500 Westchester Avenue
- Purchase
- New York, NY 10577
- United States
+1 (412) 000-0000
Cognition Therapeutics Timeline
Cognition Therapeutics Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.84 | $1.64 | $1.50 - $13.80 | $37.1M | 22.6M | 55K | -$0.87 |
Cognition Therapeutics Financials Summary
|
In Thousands, USD |
TTM 31-Mar-2022 | FY 2021 31-Dec-2021 | FY 2020 31-Dec-2020 | FY 2019 31-Dec-2019 |
|---|---|---|---|---|
| EV | 7,370 | 215,721 | ||
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (15,161) | (10,730) | (5,990) | (3,737) |
| Net Income | (15,777) | (11,716) | (7,839) | (4,842) |
| Total Assets | 58,696 | 59,137 | 7,119 | 7,459 |
| Total Debt | 1,395 | 0 | 12,852 | 6,901 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Cognition Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Cognition Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Cognition Therapeutics Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of inn
Drug Discovery
New York, NY
21
As of 2021
000.00
0000
0000-00-00
00000000
000.00
000 00
ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
0000 000000000
Boston, MA
0
As of 0000
000.00
0000000000 0
000.00
000000
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000 000000000
Clarksville, MD
0
As of 0000
00.000
00000000000
Add Comparison
Cognition Therapeutics Competitors (47)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| EIP Pharma | Venture Capital-Backed | Boston, MA | 0 | 000.00 | 0000000000 0 | 000.00 |
| 000000000000 | Venture Capital-Backed | Clarksville, MD | 0 | 00.000 | 00000000000 | |
| 0000000 | Venture Capital-Backed | Framingham, MA | 00 | 000.00 | 00000000000 | 000.00 |
| 0000000 0000000000 | Venture Capital-Backed | Newton, MA | 0 | 000.00 | 00000000000 | 000.00 |
| 0000 000000 | Formerly VC-backed | San Diego, CA | 00 | 00000 | 00000000 | 00000 |
Cognition Therapeutics Patents
Cognition Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| US-20200338045-A1 | Isoindoline compositions and methods for treating neurodegenerative disease | Pending | 01-Nov-2017 | 00000000000 | |
| EP-3704092-A1 | Isoindoline compositions and methods for treating neurodegenerative disease | Pending | 01-Nov-2017 | 00000000000 | |
| EP-3704092-A4 | Isoindoline compositions and methods for treating neurodegenerative disease | Pending | 01-Nov-2017 | 00000000000 | |
| AU-2018269964-A1 | Compositions for treating neurodegenerative diseases | Pending | 15-May-2017 | 00000000000 | |
| EP-3634394-A1 | Compositions for treating neurodegenerative diseases | Pending | 15-May-2017 | C07D295/192 |
Cognition Therapeutics Executive Team (11)
Cognition Therapeutics Board Members (14)
| Name | Representing | Role | Since |
|---|---|---|---|
| Aaron Fletcher Ph.D | Bios Partners | Board Member | 000 0000 |
| Brett Monia Ph.D | Self | Board Member | 000 0000 |
| Jack Khattar | Self | Chairman & Board Member | 000 0000 |
| Lisa Ricciardi | Cognition Therapeutics | Chief Executive Officer & Board Member | 000 0000 |
| Peggy Wallace | Golden Seeds | Board Member | 000 0000 |
Cognition Therapeutics Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Cognition Therapeutics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|